PLAGL2 promotes HCC progression by recruiting tumour‐associated macrophages via CCL2/CCR2 signalling
PLAGL2 participates in the chemotaxis of TAMs and the regulation of M2 polarisation through the CCL2-CCR2 axis, thereby promoting an immunosuppressive microenvironment in HCC. Additionally, this study demonstrated that PLAGL2 serves as a novel transcription factor for CCL2, suggesting that PLAGL2 is a potential drug target for the treatment of HCC.
Authors
- Jiaping Ni (ORCID: https://orcid.org/0000-0001-8179-3740)
- Weijun Zhao (ORCID: https://orcid.org/0000-0002-1643-2903)
- Shentian Zhuang (ORCID: https://orcid.org/0000-0002-7282-5779)
- Binghua Li (ORCID: https://orcid.org/0000-0001-7209-2854)
- Jingtong Li
- Yumeng Shen
- Yuyuan Chen (ORCID: https://orcid.org/0000-0001-5948-4685)
- Weiwei Hu (ORCID: https://orcid.org/0000-0001-6916-3746)
- Yanchao Xu (ORCID: https://orcid.org/0000-0002-1112-6026)
- Zijie Wu (ORCID: https://orcid.org/0000-0002-7378-3726)
- Dongqing Zhai
Institutions
- China Pharmaceutical University (CN)
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1111/bph.70295
- Citations
- 1
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.80